Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.5.0.2
Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Accrued expenses:    
Professional fees $ 1,389 $ 382
Salaries, bonuses and related benefits 1,777 2,492
Ovamed manufacturing rights - short term component 750 1,500
Research and development 788 810
Dr. Falk Pharma milestone 2,802 2,717
Accrued royalty and coupons 301 0
Lease impairment 95 146
Other 703 523
Total accrued expenses 8,605 8,570
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 4,583 584
Total other long-term liabilities $ 4,583 $ 584